Information Provided By:
Fly News Breaks for November 8, 2019
Nov 8, 2019 | 05:38 EDT
Goldman Sachs analyst Graig Suvannavejh initiated coverage of Portola Pharmaceuticals with a Neutral rating and $135 price target. The analyst views the shares as fairy valued as "Andexxa launch execution holds the key."
News For PTLA From the Last 2 Days
There are no results for your query PTLA